{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T20:41:56Z","timestamp":1773088916216,"version":"3.50.1"},"reference-count":70,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.autrev.2023.103439","type":"journal-article","created":{"date-parts":[[2023,9,9]],"date-time":"2023-09-09T08:58:02Z","timestamp":1694249882000},"page":"103439","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Is cyclophosphamide still the gold standard in early severe rapidly progressive systemic sclerosis?"],"prefix":"10.1016","volume":"23","author":[{"given":"Corrado","family":"Campochiaro","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yannick","family":"Allanore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yolanda","family":"Braun-Moscovici","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Matucci-Cerinic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Balbir-Gurman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10373","key":"10.1016\/j.autrev.2023.103439_bb0005","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/S0140-6736(22)01692-0","article-title":"Systemic sclerosis","volume":"401","author":"Volkmann","year":"2023","journal-title":"Lancet Lond Engl [Internet]"},{"issue":"6","key":"10.1016\/j.autrev.2023.103439_bb0010","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1136\/ard.2006.062901","article-title":"Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database","volume":"66","author":"Walker","year":"2007","journal-title":"Ann Rheum Dis [Internet]"},{"issue":"1","key":"10.1016\/j.autrev.2023.103439_bb0015","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s13075-019-1919-6","article-title":"Skin thickness score as a surrogate marker of organ involvements in systemic sclerosis: a retrospective observational study","volume":"21","author":"Matsuda","year":"2019","journal-title":"Arthritis Res Ther"},{"issue":"10","key":"10.1016\/j.autrev.2023.103439_bb0020","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1136\/ard.2009.114264","article-title":"Causes and risk factors for death in systemic sclerosis: a study from the EULAR scleroderma trials and research (EUSTAR) database","volume":"69","author":"Tyndall","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"43","key":"10.1016\/j.autrev.2023.103439_bb0025","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000001728","article-title":"Registry of the Spanish network for systemic sclerosis: survival, prognostic factors, and causes of death","volume":"94","author":"Sime\u00f3n-Aznar","year":"2015","journal-title":"Medicine (Baltimore)"},{"issue":"7","key":"10.1016\/j.autrev.2023.103439_bb0030","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1093\/rheumatology\/kez529","article-title":"Skin improvement is a surrogate for favourable changes in other organ systems in early diffuse cutaneous systemic sclerosis","volume":"59","author":"Nevskaya","year":"2020","journal-title":"Rheumatol Oxf Engl."},{"issue":"6","key":"10.1016\/j.autrev.2023.103439_bb0035","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1002\/1529-0131(200106)44:6<1351::AID-ART227>3.0.CO;2-I","article-title":"A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma","volume":"44","author":"Pope","year":"2001","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.autrev.2023.103439_bb0040","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1093\/rheumatology\/35.4.364","article-title":"Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomized double-blind trial, followed by a 24 week observational trial","volume":"35","author":"van den Hoogen","year":"1996","journal-title":"Br J Rheumatol"},{"issue":"8","key":"10.1016\/j.autrev.2023.103439_bb0045","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1002\/art.11081","article-title":"Effects of oral cyclophosphamide and prednisolone therapy on the endothelial functions and clinical findings in patients with early diffuse systemic sclerosis","volume":"48","author":"Apras","year":"2003","journal-title":"Arthritis Rheum"},{"issue":"4\u20135","key":"10.1016\/j.autrev.2023.103439_bb0050","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s10067-003-0733-2","article-title":"The efficacy of oral cyclophosphamide plus prednisolone in early diffuse systemic sclerosis","volume":"22","author":"Calguneri","year":"2003","journal-title":"Clin Rheumatol"},{"issue":"1","key":"10.1016\/j.autrev.2023.103439_bb0055","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1080\/03009740510026896","article-title":"Low-dose intravenous cyclophosphamide in systemic sclerosis: an open prospective efficacy study in patients with early diffuse disease","volume":"35","author":"Valentini","year":"2006","journal-title":"Scand J Rheumatol"},{"issue":"2","key":"10.1016\/j.autrev.2023.103439_bb0060","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s10067-005-1157-y","article-title":"A randomized unblinded trial of cyclophosphamide versus azathioprine in the treatment of systemic sclerosis","volume":"25","author":"Nadashkevich","year":"2006","journal-title":"Clin Rheumatol"},{"issue":"4","key":"10.1016\/j.autrev.2023.103439_bb0065","first-page":"613","article-title":"Twelve-month azathioprine as maintenance therapy in early diffuse systemic sclerosis patients treated for 1-year with low dose cyclophosphamide pulse therapy","volume":"25","author":"Paone","year":"2007","journal-title":"Clin Exp Rheumatol"},{"issue":"7","key":"10.1016\/j.autrev.2023.103439_bb0070","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1136\/annrheumdis-2016-210503","article-title":"Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS)","volume":"76","author":"Herrick","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"25","key":"10.1016\/j.autrev.2023.103439_bb0075","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1056\/NEJMoa055120","article-title":"Cyclophosphamide versus placebo in scleroderma lung disease","volume":"354","author":"Tashkin","year":"2006","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.autrev.2023.103439_bb0080","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/S2213-2600(16)30152-7","article-title":"Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial","volume":"4","author":"Tashkin","year":"2016","journal-title":"Lancet Respir Med"},{"issue":"7","key":"10.1016\/j.autrev.2023.103439_bb0085","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1002\/art.40114","article-title":"Mycophenolate mofetil versus placebo for systemic sclerosis-related interstitial lung disease: an analysis of scleroderma lung studies I and II","volume":"69","author":"Volkmann","year":"2017","journal-title":"Arthritis Rheumatol Hoboken NJ."},{"issue":"3","key":"10.1016\/j.autrev.2023.103439_bb0090","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1002\/acr.23282","article-title":"Efficacy of mycophenolate mofetil and oral cyclophosphamide on skin thickness: post hoc analyses from two randomized placebo-controlled trials","volume":"70","author":"Namas","year":"2018","journal-title":"Arthritis Care Res"},{"issue":"2 Suppl 76","key":"10.1016\/j.autrev.2023.103439_bb0095","first-page":"166","article-title":"Treatment of early diffuse systemic sclerosis skin disease","volume":"31","author":"Frech","year":"2013","journal-title":"Clin Exp Rheumatol"},{"issue":"8","key":"10.1016\/j.autrev.2023.103439_bb0100","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1136\/annrheumdis-2016-209909","article-title":"Update of EULAR recommendations for the treatment of systemic sclerosis","volume":"76","author":"Kowal-Bielecka","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.autrev.2023.103439_bb0105","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1002\/art.40560","article-title":"Treatment algorithms for systemic sclerosis according to experts","volume":"70","author":"Fern\u00e1ndez-Codina","year":"2018","journal-title":"Arthritis Rheumatol Hoboken NJ"},{"issue":"7","key":"10.1016\/j.autrev.2023.103439_bb0110","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1093\/rheumatology\/kez487","article-title":"Treatment with cyclophosphamide i.v. pulse therapy is an option for effective treatment of skin fibrosis in patients with early systemic sclerosis","volume":"59","author":"Kersten","year":"2020","journal-title":"Rheumatol Oxf Engl."},{"issue":"24","key":"10.1016\/j.autrev.2023.103439_bb0115","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1001\/jama.2014.6368","article-title":"Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial","volume":"311","author":"van Laar","year":"2014","journal-title":"JAMA."},{"issue":"9790","key":"10.1016\/j.autrev.2023.103439_bb0120","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/S0140-6736(11)60982-3","article-title":"Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial","volume":"378","author":"Burt","year":"2011","journal-title":"Lancet Lond Engl"},{"issue":"1","key":"10.1016\/j.autrev.2023.103439_bb0125","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1056\/NEJMoa1703327","article-title":"Myeloablative autologous stem-cell transplantation for severe scleroderma","volume":"378","author":"Sullivan","year":"2018","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.autrev.2023.103439_bb0130","doi-asserted-by":"crossref","first-page":"375","DOI":"10.3324\/haematol.2019.230128","article-title":"Autologous stem cell transplantation for progressive systemic sclerosis: a prospective non-interventional study from the European Society for Blood and Marrow Transplantation Autoimmune Disease Working Party","volume":"106","author":"Henes","year":"2021","journal-title":"Haematologica."},{"issue":"2","key":"10.1016\/j.autrev.2023.103439_bb0135","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1002\/art.40358","article-title":"Belimumab for the treatment of early diffuse systemic sclerosis: results of a randomized, double-blind, placebo-controlled, pilot trial","volume":"70","author":"Gordon","year":"2018","journal-title":"Arthritis Rheumatol Hoboken NJ"},{"issue":"1","key":"10.1016\/j.autrev.2023.103439_bb0140","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/art.41055","article-title":"Abatacept in early diffuse cutaneous systemic sclerosis: results of a phase II investigator-initiated, multicenter, double-blind, randomized, placebo-controlled trial","volume":"72","author":"Khanna","year":"2020","journal-title":"Arthritis Rheumatol Hoboken NJ"},{"issue":"5","key":"10.1016\/j.autrev.2023.103439_bb0145","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1136\/annrheumdis-2019-216823","article-title":"Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): randomised, double-blind, placebo-controlled multicentre trial","volume":"79","author":"Khanna","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"10.1016\/j.autrev.2023.103439_bb0150","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/S2213-2600(20)30318-0","article-title":"Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"8","author":"Khanna","year":"2020","journal-title":"Lancet Respir Med"},{"issue":"4","key":"10.1016\/j.autrev.2023.103439_bb0155","doi-asserted-by":"crossref","first-page":"124","DOI":"10.55563\/clinexprheumatol\/i80zh7","article-title":"A randomised, double-blind, placebo-controlled phase 3 study of lenabasum in diffuse cutaneous systemic sclerosis: RESOLVE-1 design and rationale","volume":"39 Suppl 131","author":"Spiera","year":"2021","journal-title":"Clin Exp Rheumatol"},{"issue":"12","key":"10.1016\/j.autrev.2023.103439_bb0160","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1136\/annrheumdis-2020-218447","article-title":"A randomised, double-blind, placebo-controlled, 24-week, phase II, proof-of-concept study of romilkimab (SAR156597) in early diffuse cutaneous systemic sclerosis","volume":"79","author":"Allanore","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"10.1016\/j.autrev.2023.103439_bb0165","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1093\/rheumatology\/key213","article-title":"Intravenous cyclophosphamide vs rituximab for the treatment of early diffuse scleroderma lung disease: open label, randomized, controlled trial","volume":"57","author":"Sircar","year":"2018","journal-title":"Rheumatol Oxf Engl."},{"issue":"1","key":"10.1016\/j.autrev.2023.103439_bb0170","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s13075-020-2113-6","article-title":"Early trajectories of skin thickening are associated with severity and mortality in systemic sclerosis","volume":"22","author":"Ledoult","year":"2020","journal-title":"Arthritis Res Ther"},{"issue":"8","key":"10.1016\/j.autrev.2023.103439_bb0175","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/j.cell.2022.03.011","article-title":"LGR5 expressing skin fibroblasts define a major cellular hub perturbed in scleroderma","volume":"185","author":"Gur","year":"2022","journal-title":"Cell."},{"issue":"2","key":"10.1016\/j.autrev.2023.103439_bb0180","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1093\/rheumatology\/keac410","article-title":"Macrophages as determinants and regulators of fibrosis in systemic sclerosis","volume":"62","author":"Al-Adwi","year":"2023","journal-title":"Rheumatol Oxf Engl."},{"issue":"2","key":"10.1016\/j.autrev.2023.103439_bb0185","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1136\/annrheumdis-2020-217840","article-title":"Machine learning integration of scleroderma histology and gene expression identifies fibroblast polarisation as a hallmark of clinical severity and improvement","volume":"80","author":"Showalter","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.autrev.2023.103439_bb0190","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1093\/rheumatology\/ket312","article-title":"Is immunosuppressive therapy the anchor treatment to achieve remission in systemic sclerosis?","volume":"53","author":"Cappelli","year":"2014","journal-title":"Rheumatol Oxf Engl"},{"issue":"1","key":"10.1016\/j.autrev.2023.103439_bb0195","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/ar2576","article-title":"Cyclophosphamide in systemic sclerosis: still in search of a \u201creal life\u201d scenario","volume":"11","author":"Miniati","year":"2009","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"10.1016\/j.autrev.2023.103439_bb0200","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/s13075-021-02536-5","article-title":"An update on targeted therapies in systemic sclerosis based on a systematic review from the last 3years","volume":"23","author":"Campochiaro","year":"2021","journal-title":"Arthritis Res Ther"},{"issue":"12","key":"10.1016\/j.autrev.2023.103439_bb0205","doi-asserted-by":"crossref","first-page":"3962","DOI":"10.1002\/art.22204","article-title":"A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma","volume":"54","author":"Hoyles","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"45","key":"10.1016\/j.autrev.2023.103439_bb0210","first-page":"3641","article-title":"Randomized control multi-center clinical study of mycophenolate mofetil and cyclophosphamide in the treatment of connective tissue disease related interstitial lung disease","volume":"95","author":"Zhang","year":"2015","journal-title":"Zhonghua Yi Xue Za Zhi"},{"issue":"5","key":"10.1016\/j.autrev.2023.103439_bb0215","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1136\/ard.2008.096677","article-title":"EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR)","volume":"68","author":"Kowal-Bielecka","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.autrev.2023.103439_bb0220","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S2213-2600(22)00359-9","article-title":"Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial","volume":"11","author":"Maher","year":"2023","journal-title":"Lancet Respir Med"},{"issue":"3","key":"10.1016\/j.autrev.2023.103439_bb0225","first-page":"161","article-title":"Intravenous versus oral cyclophosphamide for lung and\/or skin fibrosis in systemic sclerosis: an indirect comparison from EUSTAR and randomised controlled trials","volume":"38 Suppl 125","author":"Bruni","year":"2020","journal-title":"Clin Exp Rheumatol"},{"issue":"5","key":"10.1016\/j.autrev.2023.103439_bb0230","first-page":"838","article-title":"Cyclophosphamide and low-dose prednisone therapy in patients with systemic sclerosis (scleroderma) with interstitial lung disease","volume":"20","author":"Silver","year":"1993","journal-title":"J Rheumatol"},{"issue":"12","key":"10.1016\/j.autrev.2023.103439_bb0235","doi-asserted-by":"crossref","first-page":"947","DOI":"10.7326\/0003-4819-132-12-200006200-00004","article-title":"Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis","volume":"132","author":"White","year":"2000","journal-title":"Ann Intern Med"},{"issue":"5","key":"10.1016\/j.autrev.2023.103439_bb0240","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1164\/rccm.201709-1845OC","article-title":"Reliability and minimal clinically important differences of forced vital capacity: results from the Scleroderma Lung Studies (SLS-I and SLS-II)","volume":"197","author":"Kafaja","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.autrev.2023.103439_bb0245","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1136\/annrheumdis-2018-213708","article-title":"Short-term progression of interstitial lung disease in systemic sclerosis predicts long-term survival in two independent clinical trial cohorts","volume":"78","author":"Volkmann","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.autrev.2023.103439_bb0250","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1177\/0272989X08317015","article-title":"Oral cyclophosphamide for active scleroderma lung disease: a decision analysis","volume":"28","author":"Khanna","year":"2008","journal-title":"Med Decis Mak Int J Soc Med Decis Mak"},{"issue":"1","key":"10.1016\/j.autrev.2023.103439_bb0255","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1186\/s13075-021-02548-1","article-title":"Clinical characteristics, visceral involvement, and mortality in at-risk or early diffuse systemic sclerosis: a longitudinal analysis of an observational prospective multicenter US cohort","volume":"23","author":"Jaafar","year":"2021","journal-title":"Arthritis Res Ther"},{"issue":"11","key":"10.1016\/j.autrev.2023.103439_bb0260","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1111\/1346-8138.15079","article-title":"Rituximab therapy is more effective than cyclophosphamide therapy for Japanese patients with anti-topoisomerase I-positive systemic sclerosis-associated interstitial lung disease","volume":"46","author":"Ebata","year":"2019","journal-title":"J Dermatol"},{"issue":"26","key":"10.1016\/j.autrev.2023.103439_bb0265","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa1903076","article-title":"Nintedanib for systemic sclerosis-associated interstitial lung disease","volume":"380","author":"Distler","year":"2019","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.autrev.2023.103439_bb0270","doi-asserted-by":"crossref","first-page":"4491","DOI":"10.1093\/rheumatology\/keac136","article-title":"Clinical worsening following discontinuation of tocilizumab in diffuse cutaneous systemic sclerosis: a single-centre experience in Japan","volume":"61","author":"Isomura","year":"2022","journal-title":"Rheumatol Oxf Engl."},{"issue":"6","key":"10.1016\/j.autrev.2023.103439_bb0275","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1136\/annrheumdis-2014-205226","article-title":"Prediction of worsening of skin fibrosis in patients with diffuse cutaneous systemic sclerosis using the EUSTAR database","volume":"74","author":"Maurer","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.autrev.2023.103439_bb0280","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s13075-019-1809-y","article-title":"Minimal clinically important differences for the modified Rodnan skin score: results from the Scleroderma Lung Studies (SLS-I and SLS-II)","volume":"21","author":"Khanna","year":"2019","journal-title":"Arthritis Res Ther"},{"issue":"10","key":"10.1016\/j.autrev.2023.103439_bb0285","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.3899\/jrheum.090372","article-title":"Measures of response in clinical trials of systemic sclerosis: the Combined Response Index for Systemic Sclerosis (CRISS) and Outcome Measures in Pulmonary Arterial Hypertension related to Systemic Sclerosis (EPOSS)","volume":"36","author":"Khanna","year":"2009","journal-title":"J Rheumatol"},{"issue":"3S","key":"10.1016\/j.autrev.2023.103439_bb0290","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.semarthrit.2019.09.019","article-title":"Challenges in systemic sclerosis trial design","volume":"49","author":"Denton","year":"2019","journal-title":"Semin Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.autrev.2023.103439_bb0295","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002371","article-title":"Recommendations for the execution and reporting of skin ultrasound in systemic sclerosis: an international collaboration under the WSF skin ultrasound group","volume":"8","author":"Santiago","year":"2022","journal-title":"RMD Open"},{"issue":"16","key":"10.1016\/j.autrev.2023.103439_bb0300","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1080\/14656566.2020.1793960","article-title":"An update on the pharmacotherapeutic options and treatment strategies for systemic sclerosis","volume":"21","author":"McMahan","year":"2020","journal-title":"Expert Opin Pharmacother"},{"issue":"11","key":"10.1016\/j.autrev.2023.103439_bb0305","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1080\/1744666X.2021.1836962","article-title":"The power of the EUSTAR cohort: key findings to date and implications for management of systemic sclerosis patients","volume":"16","author":"Benvenuti","year":"2020","journal-title":"Expert Rev Clin Immunol"},{"issue":"4","key":"10.1016\/j.autrev.2023.103439_bb0310","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1080\/13543784.2020.1743973","article-title":"Drugs in phase I and phase II clinical trials for systemic sclerosis","volume":"29","author":"Chung","year":"2020","journal-title":"Expert Opin Investig Drugs"},{"issue":"6","key":"10.1016\/j.autrev.2023.103439_bb0315","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1136\/annrheumdis-2013-204522","article-title":"Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group","volume":"74","author":"Jordan","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.autrev.2023.103439_bb0320","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s12931-022-02292-3","article-title":"Expert consensus on the management of systemic sclerosis-associated interstitial lung disease","volume":"24","author":"Rahaghi","year":"2023","journal-title":"Respir Res"},{"issue":"7","key":"10.1016\/j.autrev.2023.103439_bb0325","doi-asserted-by":"crossref","first-page":"600","DOI":"10.3390\/jpm11070600","article-title":"Rituximab as a treatment option after autologous hematopoietic stem cell transplantation in a patient with systemic sclerosis","volume":"11","author":"Gressenberger","year":"2021","journal-title":"J Pers Med"},{"issue":"12","key":"10.1016\/j.autrev.2023.103439_bb0330","doi-asserted-by":"crossref","first-page":"e743","DOI":"10.1016\/S2665-9913(20)30237-X","article-title":"Safety and efficacy of abatacept in early diffuse cutaneous systemic sclerosis (ASSET): open-label extension of a phase 2, double-blind randomised trial","volume":"2","author":"Chung","year":"2020","journal-title":"Lancet Rheumatol"},{"issue":"8","key":"10.1016\/j.autrev.2023.103439_bb0335","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1038\/jid.2013.130","article-title":"Molecular signatures in skin associated with clinical improvement during mycophenolate treatment in systemic sclerosis","volume":"133","author":"Hinchcliff","year":"2013","journal-title":"J Invest Dermatol"},{"issue":"12","key":"10.1016\/j.autrev.2023.103439_bb0340","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1136\/annrheumdis-2020-217033","article-title":"Machine learning predicts stem cell transplant response in severe scleroderma","volume":"79","author":"Franks","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.autrev.2023.103439_bb0345","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1080\/14712598.2023.2196009","article-title":"Advances in biological and targeted therapies for systemic sclerosis","volume":"23","author":"Mulcaire-Jones","year":"2023","journal-title":"Expert Opin Biol Ther"},{"issue":"6","key":"10.1016\/j.autrev.2023.103439_bb0350","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1080\/13543784.2021.1923693","article-title":"New promising drugs for the treatment of systemic sclerosis: pathogenic considerations, enhanced classifications, and personalized medicine","volume":"30","author":"Lescoat","year":"2021","journal-title":"Expert Opin Investig Drugs"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997223001738?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997223001738?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,5]],"date-time":"2024-04-05T07:23:28Z","timestamp":1712301808000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997223001738"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":70,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S1568997223001738"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2023.103439","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Is cyclophosphamide still the gold standard in early severe rapidly progressive systemic sclerosis?","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2023.103439","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103439"}}